Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Purchased by Promethos Capital LLC

Promethos Capital LLC grew its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 402.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 677,184 shares of the company's stock after acquiring an additional 542,450 shares during the quarter. Dr. Reddy's Laboratories comprises 3.8% of Promethos Capital LLC's holdings, making the stock its 6th largest position. Promethos Capital LLC owned 0.08% of Dr. Reddy's Laboratories worth $10,693,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in RDY. State Street Corp increased its holdings in Dr. Reddy's Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company's stock worth $72,292,000 after purchasing an additional 16,641 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Dr. Reddy's Laboratories in the third quarter valued at about $464,000. Geode Capital Management LLC increased its position in shares of Dr. Reddy's Laboratories by 109.3% in the third quarter. Geode Capital Management LLC now owns 13,254 shares of the company's stock valued at $1,053,000 after buying an additional 6,920 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Dr. Reddy's Laboratories during the third quarter valued at $276,000. Finally, World Investment Advisors LLC acquired a new position in Dr. Reddy's Laboratories in the 3rd quarter valued at $3,459,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Stock Up 1.8 %

NYSE RDY traded up $0.25 on Friday, reaching $13.69. The stock had a trading volume of 2,412,404 shares, compared to its average volume of 1,435,918. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $11.42 billion, a price-to-earnings ratio of 21.79 and a beta of 0.51. The business has a 50 day moving average price of $13.16 and a 200 day moving average price of $14.31. Dr. Reddy's Laboratories Limited has a 1 year low of $12.26 and a 1 year high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Nomura downgraded Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.